Is It Time To Reassess National Health Investors (NHI) After Recent Share Price Softness

• Wondering if National Health Investors is priced fairly today or if the current share price leaves some room on the table? This overview walks through what the recent numbers may be saying about value.
• The stock closed at US$80.86, with returns of 5.2% year to date and 14.2% over the last year, while the past 7 and 30 days have seen declines of 2.1% and 3.8% respectively.
• Recent coverage has focused on how real estate investment trusts are responding to changing conditions in healthcare property markets and funding costs, which has shaped sentiment toward National Health Investors. Alongside this, investors have been watching sector level updates and portfolio announcements from peers, using them as reference points for how to think about National Health Investors' pricing.
• National Health Investors currently holds a valuation score of 4 out of 6. Next up is a closer look at how different valuation methods line up on this stock, and why there may be an even better way to think about value by the end of the article.

Find out why National Health Investors's 14.2% return over the last year is lagging behind its peers.

Approach 1: National Health Investors Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a company could be worth by projecting its future adjusted funds from operations and then discounting those cash flows back to today in dollar terms.

For National Health Investors, the latest twelve months free cash flow stands at about $218.7 million. Analysts and extrapolated estimates point to projected free cash flow of $388.6 million in 2030, using a 2 stage Free Cash Flow to Equity approach based on Adjusted Funds From Operations. Ten year projections, which combine analyst inputs for the earlier years and Simply Wall St extrapolations for later years, are discounted back to reach a present value estimate.

Based on these inputs, the DCF model indicates an intrinsic value of about $195.16 per share. Compared with the recent share price of $80.86, this implies a discount of 58.6%, meaning the stock is currently assessed as materially undervalued by this method.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests National Health Investors is undervalued by 58.6%. Track this in your watchlist or portfolio, or discover 58 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for National Health Investors.

Approach 2: National Health Investors Price vs Earnings

For a profitable company, the P/E ratio is a straightforward way to think about what you are paying for each dollar of earnings. It ties the share price directly to current earnings, which makes it a commonly used yardstick when those earnings are positive and reasonably stable.

What counts as a “normal” P/E usually reflects how the market views a company’s growth potential and risk. Higher expected growth or lower perceived risk can justify a higher P/E, while lower growth or higher risk may point to a lower multiple being more appropriate.

National Health Investors currently trades on a P/E of 27.60x. This sits above the Health Care REITs industry average P/E of 23.18x and also above the peer group average of 79.91x, which in this case is heavily skewed by higher valued names. Simply Wall St’s Fair Ratio for National Health Investors is 37.62x, which is the P/E level suggested by its earnings growth profile, industry, profit margins, market cap and risk factors.

The Fair Ratio helps you look past simple peer and industry comparisons because it adjusts for those company specific characteristics. Since the current P/E of 27.60x is below the Fair Ratio of 37.62x, this approach points to the shares trading at a discount to that model based assessment.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your National Health Investors Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St’s Community page let you turn your view of National Health Investors into a clear story that links assumptions about future revenue, earnings and margins to a financial forecast, a fair value and a simple comparison with today’s price. It updates that story automatically when new news or earnings arrive, and shows how different investors can see the same stock differently. For example, one Narrative might echo the analyst consensus fair value of about US$89.25 based on expectations for revenue of US$582.3 million, earnings of US$213.2 million and a P/E of 27.9x in 2029. Another more cautious Narrative could lean on the same risks around occupancy, tenant concentration and funding to support a lower fair value, giving you a clear, side by side sense of whether you think the shares are above or below what you consider reasonable.

Do you think there's more to the story for National Health Investors? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com